Asa Ren, a leading DNA data startup based in Indonesia, has announced the closing of a new early stage round of fundings of $8.15 million. This oversubscribed round was co-led by Top Harvest Capital (Silicon Valley USA), Kejora Capital (Kejora-SBI Orbit Fund and Orbit Capital Malaysia), and Marcy Venture Partners (Silicon Valley USA), with participation from Northstar Ventures, Naya Capital, PT Diagnos Laboratorium Utama Tbk, and a number of prominent angel investors.

As part of the round, Kejora Capital's founder and managing partner Andy Zain, will join the company's board of directors along with InterBIO CEO, Irawan Mulyadi.

With this funding, Asa Ren aims to enable innovation in Indonesia's healthcare industry through the utilisation of longitudinal and genomic data for accelerating drug discovery and personalised treatments. Currently, Asa Ren provides a direct-to-consumer DNA test that offers more than 360 reports - including predisposed health risks, ancestry, and other reports for adults, young parents and children.

To a greater extent, the new capital injection will allow the company to expand its efforts in deepening its digital capabilities, developing clinical bioinformatics, an electronic health passport, and a clinico-genomic database focused on non-communicable diseases. In addition, the company aims to add medical diagnosis and complete health data of the customers.

Asa Ren has signed service agreements with more than 47 prominent hospital and clinic partners and is expecting to grow its distribution footprint to more than 60 hospital and clinic partners by the end of 2023.